Galapagos announced plans to wind down its cell therapy business after a search for buyers produced insufficient offers, saying most non‑binding proposals came from financial investors and lacked the financing or terms to sustain the unit. The decision will result in site closures across Europe, China and the U.S. and put about 365 jobs at risk. Company filings and press releases said Galapagos will continue to consider acquisition offers while executing an orderly wind‑down. Management framed the move as refocusing resources on core programs after concluding the cell therapy unit could not be viably divested on acceptable terms. The outcome underscores the commercial and capital challenges in sustaining early‑stage cell therapy operations without committed strategic acquirers or clear financing paths, and it signals consolidation pressure in cell therapy manufacturing and clinical development.